Altre lingue ProMIS Neurosciences, Inc.

Azioni

PMN

CA74346M4065

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 10/05/2024			Variaz. 5gg	Var. 1 gen.
1,89 ^USD	+5,59%		-3,57%	+64,35%

30/04	ProMIS Neurosciences, Inc. pubblica uno studio che evidenzia la selettività degli oligomeri e i vantaggi degli anticorpi diretti contro l'amiloide-beta	CI
09/04	ProMIS Neurosciences Inc. pubblica nel Journal of Biological Chemistry l'interazione tra le proteine patogene come obiettivo terapeutico per la SLA	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	30/04
ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	30/04
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS	09/04
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	09/04
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	05/04
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	04/04
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights	01/04
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
ProMIS Neurosciences : Corporate Overview	29/03
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio	11/03
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference	22/02
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine	22/01
ProMIS Neurosciences Issues Letter to Shareholders	08/01
ProMIS Neurosciences, Inc. Announces Management Changes	03/01
ProMIS Neurosciences, Inc. Announces CEO Changes	03/01
ProMIS Neurosciences, Inc. Announces Leadership Transition	03/01
ProMIS Neurosciences Announces Publication on Novel Target for ALS	20/12
ProMIS Neurosciences Announces Publication on Novel Target for ALS	20/12
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease	20/11
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease	20/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ProMIS Neurosciences, Inc.

Azioni

PMN

CA74346M4065

Altre lingue

Filtri